The Great Drive to Develop Treatments for NASH continues with Second Genome Presenting Data Supporting Development of Its P2X7 Inhibitor, SGM-1019

Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in healthy volunteers with its lead drug candidate SGM-1019, a P2X7 inhibitor currently being developed for treatment of nonalcoholic steatohepatitis (NASH). SGM-1019 is one of the drugs being developed in the great NASH development race. Currently there are over 60 drugs in various stages of development.